Suppr超能文献

BRACE 试验前瞻性采集数据对 COVID-19 和其他呼吸道疾病的前驱和持续症状的研究。

Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trial.

机构信息

Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Immunology, Vaccinology, Rheumatology and Infectious Diseases Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

出版信息

J Infect. 2024 Nov;89(5):106267. doi: 10.1016/j.jinf.2024.106267. Epub 2024 Sep 6.

Abstract

BACKGROUND

Some individuals have a persistence of symptoms following both COVID-19 (post-acute COVID-19 syndrome; PACS) and other viral infections. This study used prospectively collected data from an international trial to compare symptoms following COVID-19 and non-COVID-19 respiratory illness, to identify factors associated with the risk of PACS, and to explore symptom patterns before and after COVID-19 and non-COVID-19 respiratory illnesses.

METHODS

Data from a multicentre randomised controlled trial (BRACE trial) involving healthcare workers across four countries were analysed. Symptom data were prospectively collected over 12 months, allowing detailed characterisation of symptom patterns. Participants with COVID-19 and non-COVID-19 respiratory illness episodes were compared, focussing on symptom severity, duration (including PACS using NICE and WHO definitions), and pre-existing symptoms.

FINDINGS

Compared to those with a non-COVID-19 illness, participants with COVID-19 had significantly more severe illness (OR 7·4, 95%CI 5·6-9·7). Symptom duration meeting PACS definitions occurred in a higher proportion of COVID-19 cases than non-COVID-19 respiratory controls using both the NICE definition (2·5% vs 0·5%, OR 6·6, 95%CI 2·4-18·3) and the WHO definition (8·8% vs 3·7%, OR 2·5, 95%CI 1·4-4·3). When considering only participants with COVID-19, age 40-59 years (aOR 2·8, 95%CI 1·3-6·2), chronic respiratory disease (aOR 5·5, 95%CI 1·3-23·1), and pre-existing symptoms (aOR 3·0, 95%CI 1·4-6·3) were associated with an increased risk of developing PACS. Symptoms associated with PACS were also reported by participants in the months preceding their COVID-19 or non-COVID-19 respiratory illnesses (32% fatigue and muscle ache, 11% intermittent cough and shortness of breath).

INTERPRETATION

Healthcare workers with COVID-19 were more likely to have severe and longer-lasting symptoms than those with a non-COVID-19 respiratory illness, with a higher proportion meeting the WHO or NICE definitions of PACS. Age, chronic respiratory disease, and pre-existing symptoms increased the risk of developing PACS following COVID-19.

摘要

背景

一些人在感染新冠病毒(新冠后综合征;PACS)和其他病毒后仍持续存在症状。本研究使用一项国际试验前瞻性收集的数据,比较了新冠和非新冠呼吸道疾病后的症状,以确定与 PACS 风险相关的因素,并探讨新冠和非新冠呼吸道疾病前后的症状模式。

方法

对涉及四个国家的医疗保健工作者的多中心随机对照试验(BRACE 试验)的数据进行了分析。症状数据在 12 个月内进行前瞻性收集,允许对症状模式进行详细描述。比较了患有新冠和非新冠呼吸道疾病的参与者,重点关注症状严重程度、持续时间(包括使用 NICE 和世卫组织定义的 PACS)和预先存在的症状。

结果

与非新冠疾病患者相比,新冠患者的疾病严重程度显著更高(OR7.4,95%CI5.6-9.7)。使用 NICE 定义(2.5%对 0.5%,OR6.6,95%CI2.4-18.3)和世卫组织定义(8.8%对 3.7%,OR2.5,95%CI1.4-4.3),新冠病例中出现符合 PACS 定义的症状持续时间的比例均高于非新冠呼吸道对照病例。当仅考虑新冠患者时,40-59 岁年龄组(aOR2.8,95%CI1.3-6.2)、慢性呼吸道疾病(aOR5.5,95%CI1.3-23.1)和预先存在的症状(aOR3.0,95%CI1.4-6.3)与发生 PACS 的风险增加相关。在新冠或非新冠呼吸道疾病之前的几个月,参与者也报告了与 PACS 相关的症状(32%疲劳和肌肉疼痛,11%间歇性咳嗽和呼吸急促)。

结论

与非新冠呼吸道疾病相比,新冠患者更有可能出现严重和持续时间更长的症状,并且符合世卫组织或 NICE 关于 PACS 的定义的比例更高。年龄、慢性呼吸道疾病和预先存在的症状增加了新冠后发生 PACS 的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ac7/11489119/fd1201da7a79/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验